14 Nov, EOD - Indian

SENSEX 77580.31 (-0.14)

Nifty 50 23532.7 (-0.11)

Nifty Bank 50179.55 (0.18)

Nifty IT 42390.85 (0.05)

Nifty Midcap 100 54043.1 (0.45)

Nifty Next 50 67408.65 (0.46)

Nifty Pharma 21752 (-0.26)

Nifty Smallcap 100 17601.05 (0.81)

14 Nov, EOD - Global

NIKKEI 225 38642.91 (0.28)

HANG SENG 19426.34 (-0.05)

S&P 5912 (-1.31)

Login/Signup
LOGIN HERE
Cancel

Shilpa Medicare Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 530549 | NSE Symbol : SHILPAMED | ISIN : INE790G01031 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
04-Nov-2024 13-Nov-2024 Quarterly Results SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Consider The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30 September 2024 Considered and approved 1.The Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30 September 2024. A copy of Un-Audited Financial Result along with the Limited Review report is enclosed as Annexure 1. 2.Inducted Dr. Anita Bandyopadhyay, Non-Executive Independent Director as a member of Audit Committee. (As Per BSE Announcement dated on 13.11.2024)
31-Jul-2024 08-Aug-2024 Quarterly Results SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve Intimation of Board Meeting to consider the Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30 June 2024 Unaudited financial results for the quarter ended 30th June, 2024 Revised outcome of the Board meeting held on 08 August 2024 Outcome of Board Meeting (As per BSE Announcement Dated on 08/08/2024)
16-May-2024 23-May-2024 Final Dividend SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2024 inter alia to consider and approve Pursuant to the provisions of Regulation 29 of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations 2015 we hereby wish to inform you that the Meeting of the Board of Directors of Shilpa Medicare Limited is scheduled on Thursday 23 May 2024 inter alia to transact the following business items: 1. Approval of the Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and the financial year ended 31 March 2024 2. Recommendation of Dividend if any for the financial Year ended 31 March 2024 With reference to the captioned subject we hereby wish to inform you that the Board at its meeting held today i.e., on 23 May 2024 which commenced at 11.50 am and concluded at 3.45 pm has inter alia considered and approved audited financial results (Standalone and Consolidated) for the quarter and year ended 31 March 2024. Read less.. The Board has decided not to recommend any dividend for the financial year 2023-24. (As Per BSE Announcement Dated on 23.05.2024)
01-Feb-2024 08-Feb-2024 Quarterly Results SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve The Un-Audited Financial Results for the quarter and nine months ended 31 December 2023 Un-Audited standalone & consolidated financial results for the quarter and nine months ended 31 December 2023 (As per BSE Announcement Dated on 08/02/2024)
03-Nov-2023 10-Nov-2023 Quarterly Results SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve The meeting of Board of Directors of the Company is scheduled on Friday 10 November 2023 to inter alia consider the Un-audited financial results for the quarter & half year ended 30 September 2023. Un-Audited Financial results for the quarter and half year ended 30 September 2023 Intimation pursuant to reg 31A of SEBI (LODR) 2015 for reclassification from promoter/promoter group to public (As Per BSE Announcement Dated on 10.11.2023)
01-Sep-2023 01-Sep-2023 AGM This is to inform that the Board of Directors at their meeting held on 01 September 2023 which commenced at 11.20 and concluded at 13:30 have inter alia consider and approved :- 1. The Annual Report for the Financial Year 2022-23. 2. Annual General Meeting of the Members of the Company: We are pleased to inform you that the 36th Annual General Meeting of Shilpa Medicare Limited is scheduled on Friday, the 29th day of September 2023 at 11:00 AM through video conferencing (VC)/ other audio visual means (OAVM) to transact the business(es) as set forth in the notice of the meeting.
03-Aug-2023 10-Aug-2023 Quarterly Results SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve Consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended 30 June 2023 Board considered and approved the standalone & consolidated financial results for the quarter ended 30th June 2023 Unaudited standalone & consolidated financial results for the quarter ended 30th june 2023 (As Per BSE Announcement dated on 10.08.2023)
21-Jul-2023 21-Jul-2023 Preferential Issue Outcome of the meeting of Board of Directors held on 21 July 2023
20-Jun-2023 23-Jun-2023 Right Issue SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/06/2023 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors of the company will be held on Friday June 23 2023 to consider inter alia proposal of fund raising by way of Rights issue of Equity Shares subject to such Regulatory/ Statutory approvals as may be required. In accordance with SEBI (Prohibition of Insider Trading) Regulations 2015 read with the Companys code of conduct to Regulate Monitor and Report trading by Designated persons the Trading window of the The Board of Directors of the Company('Board') at its meeting held on 23 June 2023, inter-alia considered and approved the following business items: 1. Increase of Authorized Share Capital 2. Rights issue 3. Approval of Scheme of Amalgamation with Shilpa Therapeutics Private Limited (A Wholly Owned Subsidiary Company). (As Per BSE Announcement dated on 23.06.2023)
17-May-2023 25-May-2023 Accounts SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2023 inter alia to consider and approve Pursuant to the provisions of Regulation 29 of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations 2015 we hereby wish to inform you that the Meeting of the Board of Directors of Shilpa Medicare Limited is scheduled on Thursday 25 May 2023 inter alia to transact the following business items: 1. Approval of the Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and the financial year ended 31 March 2023 2. Recommendation of Dividend if any for the financial Year ended 31 March 2023
03-Feb-2023 14-Feb-2023 Quarterly Results SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve The Meeting of Board of Directors of the Company will be held on Tuesday 14th February 2023 to inter alia Consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter ended 31st December 2022 With reference to the subject cited above, this is to intimate that the Board of Directors in its meeting held on 14 February 2023 which commenced at 02.00 p.m. and concluded at 04: 03 p.m. have inter alia considered and approved Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 31 December 2022. A copy of Limited Review Report is also enclosed as Annexure 1. (As per BSE Announcement Dated on 14/02/2023)
03-Nov-2022 11-Nov-2022 Quarterly Results SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30th September 2022. With reference to the subject cited above, this is to intimate that the Board of Directors at their meeting held on 11th November 2022 which commenced at 02.00 p.m. and concluded at 05. oo p.m. have inter alia considered and approved Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30 September 2022. (As Per BSE Announcement dated on 11.11.2022)
03-Aug-2022 11-Aug-2022 Quarterly Results SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2022 inter alia to consider and approve Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June 2022 Appointment of Dr. Anita Bandyopadhyay (DIN No: 08672071), as an Additional Women Independent Director of the Company to hold office upto the date of ensuing Annual General Meeting and recommending her appointment as a Women Independent Director for a period of 3 years subject to members approval in the ensuing Annual General Meeting. (As per BSE Announcement Dated on 12/08/2022) Newspaper Publication of Un-audited Standalone and Consolidated Financial Results for the Quarter ended 30th June, 2022 published in compliance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in Soodhimool (Kannada) and Business Line (English) on 13th August 2022 (As Per BSE Announcement Dated on 13/08/2022) This is to intimate that the Board of Directors in its meeting held on 11th August 2022 which commenced at 02.30 p.m. and concluded at 6: 30 p.m. have inter alia considered and approved Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 30 June 2022. (As Per BSE Announcement Dated 11.08.2022)
16-May-2022 23-May-2022 Accounts SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2022 inter alia to consider and approve 1. Approval of the Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and the financial year ended 31 March 2022 2. Recommendation of Dividend if any for the financial Year ended 31 March 2022 Shilpa Medicare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 23, 2022, inter alia, has considered and approved the following: Recommendation of Dividend: Payment of dividend of Rs. 1.10/- (110%) per equity share of face value of Rs. 1/- each for the financial year 2021-2022, subject to approval of members in the ensuing Annual General Meeting. The audited financial results (Standalone and Consolidated) for the quarter and year ended 31 March 2022, pursuant to Regulation 33 (3) of Listing Regulations. The copy of the same including statement of assets and liabilities, statement of cash flows along with the Auditors'' Report with unmodified opinion and a declaration to the effect that the Auditors have given unmodified opinion on the Audited financial result (Standalone and Consolidated) for the year ended 31 March 2022 (Please refer Annexure 1) With reference to the captioned subject we hereby wish to inform you that the Board at its meeting held today i.e., on 23 May 2022 has inter alia considered and approved the following: 1. Approval of Financial Statements 2. Recommendation of Dividend 3. Update on Slump sale of Active Pharmaceutical Ingredient Business of the Company 4. Fund Raising plans in Shilpa Pharma Lifesciences Limited (A wholly owned subsidiary) by way of Initial Public offerings 5. Appointment of Company Secretary & Compliance Officer This is for your information and necessary records.x (As Per BSE Announcement dated on 23.05.2022)
02-Feb-2022 08-Feb-2022 Quarterly Results SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2022 inter alia to consider and approve Approval of the un-audited Standalone and Consolidated Financial Results of the Company for the Third Quarter ended 31 December 2021. Approval of Unaudited Standalone and Consolidated Financial Results of the Company for the Third Quarter ended 31 December 2021. (As per BSE Announcement Dated on 08/02/2022) With reference to the captioned subject, we hereby wish to inform that the Board of Directors at their meeting held on 08 February 2022, inter alia discussed and took note the following; Resignation of Mr. Naresh Patwari as a Non-executive Director of the Company with effect from 02 February 2022. Resignation of Mr. Piyush Goenka as an Independent Director of the Company with effect from 07 February 2022. Request you to take the same on record. (As per BSE Announcement Dated on 09/02/2022)
1 2 3